Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 27, 2026, 9:45 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 40 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Non-ST Elevation Acute Coronary Syndrome Clear all
Suspended No phase listed Observational

Infrasensor for Early Detection of a High-grade Obstructive NSTE-ACS

NCT07464704
View directory record Official record
Conditions
High Grade Obstructive NSTE-ACS
Interventions
Not listed
Lead sponsor
Remote Cardiac Enablement
Industry
Eligibility
18 Years and older
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
6
States / cities
La Jolla, California • San Francisco, California • Marietta, Georgia + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Sep 27, 2026, 9:45 PM EDT
Terminated Phase 3 Interventional

Clopidogrel and the Optimization of Gastrointestinal Events (COGENT-1)

NCT00557921
View directory record Official record
Conditions
Acute Coronary Syndrome, Myocardial Infarction, Coronary Artery Disease, Percutaneous Coronary Intervention
Interventions
CGT-2168 (clopidogrel 75 mg/omeprazole 20 mg) and aspirin, Plavix (clopidogrel 75 mg) and aspirin
Drug
Lead sponsor
Cogentus Pharmaceuticals
Industry
Eligibility
21 Years and older
Enrollment
5,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
247
States / cities
Alexander City, Alabama • Birmingham, Alabama • Geneva, Alabama + 205 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2009 · Synced Sep 27, 2026, 9:45 PM EDT
Completed No phase listed Observational Results available

ClearWay Rx Readmission Registry

NCT01673893
View directory record Official record
Conditions
Acute Myocardial Infarction
Interventions
ClearWay™ Rx catheter
Device
Lead sponsor
Cardiovascular Institute of the South Clinical Research Corporation
Other
Eligibility
18 Years to 80 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Lafayette, Louisiana
Source: ClinicalTrials.gov public record
Updated Nov 28, 2018 · Synced Sep 27, 2026, 9:45 PM EDT
Completed Not applicable Interventional

MCG Discovery Study in Emergency Departments

NCT06095557
View directory record Official record
Conditions
ACS - Acute Coronary Syndrome, NSTEMI - Non-ST Segment Elevation MI
Interventions
Sponsor MCG device
Device
Lead sponsor
SB Technology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 20, 2025 · Synced Sep 27, 2026, 9:45 PM EDT
Completed Phase 2 Interventional

Anticoagulation With rNAPc2 to Eliminate MACE/TIMI 32

NCT00116012
View directory record Official record
Conditions
Coronary Disease
Interventions
rNAPc2
Drug
Lead sponsor
ARCA Biopharma, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 28, 2006 · Synced Sep 27, 2026, 9:45 PM EDT
Completed Not applicable Interventional

HeartHome: A Nurse-Driven, Home-Based Cardiac Rehabilitation Program

NCT04131816
View directory record Official record
Conditions
Myocardial Infarction, Acute Coronary Syndrome, ST-segment Elevation Myocardial Infarction (STEMI), Non-ST-Segment Elevation Myocardial Infarction (NSTEMI), Angina, Stable
Interventions
HeartHome
Behavioral
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
40 Years to 80 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 3, 2022 · Synced Sep 27, 2026, 9:45 PM EDT
Completed No phase listed Observational

ECG Methods for the Prompt Identification of Coronary Events

NCT04237688
View directory record Official record
Conditions
Chest Pain, Myocardial Infarction, Myocardial Ischemia, Acute Coronary Syndrome
Interventions
Not listed
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
6,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2023
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 15, 2024 · Synced Sep 27, 2026, 9:45 PM EDT
Not listed No phase listed Observational

EKG Criteria and Identification of Acute Coronary Occlusion

NCT03863327
View directory record Official record
Conditions
Acute Coronary Syndrome, STEMI, STEMI - ST Elevation Myocardial Infarction, Acute Coronary Artery Thrombosis (Diagnosis), NSTEMI - Non-ST Segment Elevation MI, Non-ST Elevation Myocardial Infarction, Non ST Segment Elevation Myocardial Infarction, Non ST Segment Elevation Acute Coronary Syndrome, Non-ST Elevation Myocardial Infarction (nSTEMI), Non STEMI
Interventions
No intervention
Other
Lead sponsor
Stony Brook University
Other
Eligibility
Not listed
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
2
States / cities
Minneapolis, Minnesota • Stony Brook, New York
Source: ClinicalTrials.gov public record
Updated Mar 4, 2019 · Synced Sep 27, 2026, 9:45 PM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Safety of 12 Weeks of Dosing With GW856553 and Its Effects on Inflammatory Markers, Infarct Size, and Cardiac Function in Subjects With Myocardial Infarction Without ST-segment Elevation

NCT00910962
View directory record Official record
Conditions
Acute Coronary Syndrome
Interventions
GW856553, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
45 Years and older
Enrollment
526 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
30
States / cities
Anchorage, Alaska • Tucson, Arizona • Los Angeles, California + 27 more
Source: ClinicalTrials.gov public record
Updated Dec 6, 2017 · Synced Sep 27, 2026, 9:45 PM EDT
Completed Not applicable Interventional

Cardiac Magnetic Resonance Imaging Strategy for the Management of Patients With Acute Chest Pain and Detectable to Elevated Troponin

NCT01931852
View directory record Official record
Conditions
Acute Coronary Syndrome, Chest Pain
Interventions
Cardiac MRI, ACC/AHA Guideline adherent care
Procedure · Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
21 Years and older
Enrollment
312 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
4
States / cities
Royal Oak, Michigan • Jackson, Mississippi • Winston-Salem, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 3, 2022 · Synced Sep 27, 2026, 9:45 PM EDT
Terminated Phase 2 Interventional

Serp-1 for the Treatment of Acute Coronary Syndrome

NCT00243308
View directory record Official record
Conditions
Unstable Angina, Coronary Atherosclerosis, Coronary Restenosis
Interventions
Serine proteinase-1 (Serp-1)
Drug
Lead sponsor
Viron Therapeutics Inc
Industry
Eligibility
18 Years to 80 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
3
States / cities
Washington D.C., District of Columbia • Gainesville, Florida • Grand Rapids, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 5, 2009 · Synced Sep 27, 2026, 9:45 PM EDT
Completed Phase 2 Interventional

Safety and Tolerability of E5555 and Its Effects on Markers of Intravascular Inflammation in Subjects With Acute Coronary Syndrome

NCT00548587
View directory record Official record
Conditions
Acute Coronary Syndrome
Interventions
E5555, Placebo
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
45 Years to 80 Years
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Beloit, Wisconsin
Source: ClinicalTrials.gov public record
Updated Feb 3, 2016 · Synced Sep 27, 2026, 9:45 PM EDT
Completed Phase 3 Interventional

Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST Elevation Acute Coronary Syndromes

NCT00099788
View directory record Official record
Conditions
Myocardial Ischemia
Interventions
Ranolazine, Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
6,560 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 25, 2009 · Synced Sep 27, 2026, 9:45 PM EDT
Not yet recruiting No phase listed Observational

"Discovery2" Study of Using MCG at Emergency Departments

NCT07822581
View directory record Official record
Conditions
Acute Coronary Syndromes (ACS), Coronary Artery Disease (CAD), Chest Pain, NSTE-ACS (NSTEMI and UA)
Interventions
Magnetocardiography
Device
Lead sponsor
SB Technology, Inc.
Industry
Eligibility
22 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Sep 27, 2026, 9:45 PM EDT
Completed Phase 3 Interventional Results available

A Phase 3 Clinical Outcomes Study to Compare the Incidence of Major Adverse Cardiovascular Events in Subjects Presenting With Acute Coronary Syndrome Treated With Losmapimod Compared to Placebo (LATITUDE-TIMI 60)

NCT02145468
View directory record Official record
Conditions
Acute Coronary Syndrome
Interventions
Losmapimod 7.5 mg twice daily, Placebo twice daily, Standard therapy
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
35 Years and older
Enrollment
3,503 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
91
States / cities
Huntsville, Alabama • Cottonwood, Arizona • Tucson, Arizona + 83 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2017 · Synced Sep 27, 2026, 9:45 PM EDT
Recruiting Not applicable Interventional

Breaking Fasts Ahead of Cardiac Caths

NCT06996639
View directory record Official record
Conditions
Stable Angina (SA), Unstable Angina (UA), NSTEMI - Non-ST Segment Elevation MI
Interventions
Non-Fasting, Fasting
Behavioral
Lead sponsor
University of South Florida
Other
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Dec 15, 2025 · Synced Sep 27, 2026, 9:45 PM EDT
Terminated Phase 4 Interventional Results available

Ticagrelor vs Clopidogrel in Non-ST Elevation Acute Coronary Syndrome Patients Undergoing PCI With Bivalirudin.

NCT02052635
View directory record Official record
Conditions
Non-ST Elevation Acute Coronary Syndrome
Interventions
ticagrelor, clopidogrel
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
8
States / cities
Jacksonville, Florida • Lake Mary, Florida • Macon, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated May 26, 2016 · Synced Sep 27, 2026, 9:45 PM EDT
Completed Not applicable Interventional Results available

MBCT Delivered Via Group Videoconferencing for ACS Syndrome Patients With Depressive Symptoms

NCT04231097
View directory record Official record
Conditions
Acute Coronary Syndrome, Depression, Myocardial Infarction, Unstable Angina, STEMI, NSTEMI - Non-ST Segment Elevation MI
Interventions
MBCT intervention for ACS patients
Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
35 Years to 85 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 23, 2023 · Synced Sep 27, 2026, 9:45 PM EDT
Completed Not applicable Interventional Results available

HARMONEE - Japan-USA Harmonized Assessment by Randomized, Multi-Center Study of OrbusNEich's Combo StEnt

NCT02073565
View directory record Official record
Conditions
Coronary Arteriosclerosis, Non ST Segment Elevation Acute Coronary Syndrome
Interventions
OrbusNeich Combo stent™, Everolimus Eluting Stent (EES)
Device
Lead sponsor
OrbusNeich
Industry
Eligibility
20 Years and older
Enrollment
572 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
17
States / cities
Washington D.C., District of Columbia • Lake Worth, Florida • Miami, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated May 12, 2022 · Synced Sep 27, 2026, 9:45 PM EDT
Completed Phase 4 Interventional

Diagnosis and Treatment of Acute Coronary Syndrome in the ED & the Impact of Rapid Bedside cTnl on Outcome.

NCT00276432
View directory record Official record
Conditions
Unstable Angina, Non-ST-Elevation Myocardial Infarction
Interventions
iSTAT point of care analyzer
Device
Lead sponsor
Mayo Clinic
Other
Eligibility
21 Years and older
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 27, 2010 · Synced Sep 27, 2026, 9:45 PM EDT
Completed Not applicable Interventional Results available

PIONEER III Trial to Assess Safety and Efficacy of the BuMA Supreme™ Drug Coated Coronary Stent in Patients With Coronary Disease

NCT03168776
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
BuMA Supreme DES, Xience or Promus DES
Device
Lead sponsor
Sino Medical Sciences Technology Inc.
Industry
Eligibility
20 Years and older
Enrollment
1,629 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
40
States / cities
Birmingham, Alabama • Gilbert, Arizona • Los Angeles, California + 36 more
Source: ClinicalTrials.gov public record
Updated Jan 26, 2026 · Synced Sep 27, 2026, 9:45 PM EDT
Completed Phase 3 Interventional Results available

A Comparison of Ticagrelor (AZD6140) and Clopidogrel in Patients With Acute Coronary Syndrome

NCT00391872
View directory record Official record
Conditions
Acute Coronary Syndrome
Interventions
Ticagrelor, Clopidogrel
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
18,624 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
139
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 136 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2012 · Synced Sep 27, 2026, 9:45 PM EDT
Completed No phase listed Observational

Investigation of the Biomarker Copeptin in Patients With Acute Myocardial Infarction

NCT00952744
View directory record Official record
Conditions
Acute Coronary Syndromes
Interventions
Not listed
Lead sponsor
Brahms AG
Industry
Eligibility
18 Years and older
Enrollment
2,071 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
11
States / cities
Palo Alto, California • San Diego, California • San Francisco, California + 8 more
Source: ClinicalTrials.gov public record
Updated Jan 17, 2012 · Synced Sep 27, 2026, 9:45 PM EDT
Completed Phase 3 Interventional

SYNERGY: Open Study of Enoxaparin Versus Unfractionated Heparin in Patients With Acute Coronary Syndromes

NCT00043784
View directory record Official record
Conditions
Unstable Angina, Myocardial Infarction, Myocardial Ischemia
Interventions
enoxaparin
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
8,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 15, 2008 · Synced Sep 27, 2026, 9:45 PM EDT